Name: BPC-157/TB-500 (Wolverine)
Brand: Amino Club
SKU: prod_01KE41BS0KXPMM05AT8JMB6VCP
Availability: InStock

BPC-157/TB-500 (Wolverine) | 99%+ Pure Peptide | Amino Club | Amino Club

How the Wolverine Stack Works

Dual-Pathway Synergy

Two Mechanisms, One Goal

The Wolverine Stack combines two peptides with distinct but complementary mechanisms. BPC-157 promotes angiogenesis (blood vessel formation) through VEGFR2 signaling, while TB-500 enhances cell migration through G-actin regulation. Together, they create optimal conditions for tissue repair by addressing both vascular supply and cellular mobility.

VEGFPrimary

VEGFR2 Pathway (BPC-157)

Vascular Endothelial Growth Factor Receptor 2

Promotes new blood vessel formation
Increases blood flow to injured areas
Activates endothelial cell proliferation

ActinPrimary

G-Actin Sequestration (TB-500)

Monomeric Globular Actin Binding

Regulates cytoskeletal remodeling
Facilitates cell motility and migration
Enables wound closure mechanisms

ILKSupportive

ILK/Akt Pathway (TB-500)

Integrin-Linked Kinase Complex

Promotes cell survival signaling
Activates Akt pathway
Supports cardiac and muscle cell migration

NF-κBModulatory

Anti-Inflammatory (Both)

Inflammation Modulation Pathways

Reduces pro-inflammatory cytokines
Modulates NF-κB signaling
Promotes resolution of inflammation

GlobalRPH — BPC-157 and TB-500 Review

Why They Work Together

Complementary Regenerative Pathways

BPC-157 and TB-500 work through different but convergent mechanisms. BPC-157 promotes blood vessel formation through VEGFR2-Akt-eNOS signaling, while TB-500 promotes cell migration by regulating actin dynamics. Both reduce inflammation — creating optimal healing conditions from multiple angles.

Key synergy insight: While BPC-157 brings blood supply to injury sites, TB-500 enables cells to migrate to those sites. Together, they address both vascular and cellular requirements for tissue repair.

BPC-157 Primary ActionAngiogenesis (VEGF)

TB-500 Primary ActionCell Migration (Actin)

OverlapAnti-inflammatory

Combined EffectComprehensive repair

BPC-157 Component

VEGFR2-Akt-eNOS Signaling Cascade

BPC-157 activates the VEGFR2 pathway, triggering the Akt-eNOS cascade. This increases nitric oxide production and promotes new blood vessel formation (angiogenesis) at injury sites, ensuring adequate nutrient and oxygen delivery.

J Mol Med (2017): BPC-157 upregulates VEGFR2 expression, promotes receptor internalization, and activates VEGFR2-Akt-eNOS signaling — accelerating blood flow recovery in ischemic tissue models.

Combined Research Applications

Why researchers study these peptides together

Tendon

& LigamentBPC-157 fibroblast outgrowth + TB-500 cell migration

Complementary tissue repair mechanisms

J Applied Physiology

Wound

HealingAngiogenesis + keratinocyte migration

61% faster + increased blood supply

J Invest Dermatol

Muscle

Recovery

FAK/paxillin + actin regulation pathways

Expert Opin Biol Ther

Anti-

InflammatoryNF-κB modulation from both peptides

Dual inflammation control pathways

PMC Function Review

Musculoskeletal

Comprehensive Tissue Repair

The combination addresses multiple aspects of musculoskeletal healing: BPC-157 promotes blood vessel formation and growth factor signaling, while TB-500 enhances cell motility and cytoskeletal remodeling.

BPC-157: Cell migrationTendon fibroblasts

+70%

TB-500: Keratinocyte migration2-3× increase

+200%

BPC-157: Cell survivalUnder stress

+60%

Synergy potential: BPC-157's angiogenic effects may enhance delivery of nutrients and oxygen, while TB-500's cell migration effects bring repair cells to the injury site — a potentially complementary approach.

GlobalRPH Review (2025)

Cardiovascular

Cardiac Protection & Repair

TB-500 has shown cardioprotective effects through ILK activation, while BPC-157 promotes vascular repair. Together, they may address multiple aspects of cardiovascular healing.

TB-500: ILK activationPromotes cell survival

TB-500: Cardiomyocyte migrationEnhanced motility

BPC-157: Vascular repairVEGFR2 pathway

Both: Anti-inflammatoryReduced damage

Nature (2004)

Gastrointestinal

Gut Protection & Healing

BPC-157 was originally isolated from gastric tissue and has extensive GI research. Its cytoprotective effects may complement TB-500's tissue repair properties.

24+ hrs

BPC-157 gastric stability

BPC-157 origin: Originally isolated from gastric juice, BPC-157 demonstrates remarkable stability in the digestive system and has been extensively studied for GI protection.

World J Gastroenterology

Neurological

Neuroprotection & Recovery

Both peptides have demonstrated neuroprotective properties in preclinical models, with TB-500 promoting oligodendrogenesis and BPC-157 modulating the brain-gut axis.

TB-500: Oligodendrocytes↑ Increased in SVZ

TB-500: Myelination↑ Enhanced in striatum

BPC-157: Brain-gut axisModulatory effects

BPC-157: Dopamine systemProtective effects

J Neurol Sci (2014)

Dosing Information from Research

From clinical trials and preclinical studies

No formal combination dosing protocols have been established. Information below is derived from individual peptide studies. Researchers often combine these peptides based on independent dosing data.

BPC-157 Research

BPC-157 Preclinical Protocol

Standard research doses from animal studies range from 10 ng/kg to 10 μg/kg. Human Phase 1 trial tested oral tablets (1-6mg).

10μg/kg

Standard research dose

1-2× daily

Most common in rat studies

1-6mg

Phase 1 oral tablet

Single or 3× daily × 14d

Human trial (NCT02637284)

Effective across a 1000-fold dose range

No dose-limiting toxicity identified

Oral bioavailability confirmed (gastric stable 24+ hrs)

TB-500 Research

TB-500 Clinical Protocol

Phase 1 trial tested IV doses from 42-1260mg daily for 14 days in healthy volunteers. All doses were well tolerated.

42mg

Low dose cohort

Single, then daily × 14d

t½ = 0.95 hours

1260mg

High dose cohort

Single, then daily × 14d

t½ = 1.9 hours

3.75mg/kg

Optimal neurological dose

Calculated from preclinical

Quartic regression model

All doses well tolerated with no dose-limiting toxicities

Pharmacokinetic profile showed dose-proportional response

Half-life increased with increasing dose (0.95-1.9 hrs)

Pharmacokinetics

Pharmacokinetic Profiles

BPC-157 t½Half-life (IV/IM)<30 minutes

TB-500 t½Half-life (IV, dose-dependent)0.95-1.9 hours

BPC-157 PeakTime to maximum concentration (IM)3-9 minutes

TB-500 PeakTime to maximum concentration (IV)~15 minutes

BPC-157 Stability24+ hrs in gastric juice

Route FlexibilityBoth: SubQ, IM, IV, Oral

Short half-lives are typical for peptide drugs

BPC-157's gastric stability supports oral administration

TB-500 shows dose-proportional pharmacokinetics

Important Notes

No formal combination protocols have been established
Neither peptide is FDA approved for human use
Quality control varies significantly between sources
Both are banned by WADA since 2022 (S0 category)

Safety Profile from Research

Combined data from individual peptide studies

Both peptides have demonstrated favorable safety profiles in their respective studies. BPC-157 has extensive preclinical safety data, while TB-500 has completed Phase 1 human trials with no serious adverse events.

Common Digestive Issues

10%

Injection Site Reactions

mild

15%

Headache

mild

GI Discomfort

mild

10%

Upper Respiratory

mild

Theoretical Concerns

Theoretical Angiogenesis ConcernsPotential risks requiring further investigation

Both peptides promote angiogenesis (blood vessel growth), which raises theoretical concerns about potential effects on tumor growth. This has not been definitively studied.

Pro-angiogenic effects could theoretically affect tumors
No cancer studies have been conducted on either peptide
Long-term effects in humans unknown for both
Comprehensive cancer screening recommended before use

Discontinuation Rates

Combined Safety Summary

BPC-157 LD50Not achieved

TB-500 SAEs0 (none) in Phase 1

TB-500 DLTs0 (none) at any dose

BPC-157 Organ toxicityNone detected

BPC-157: No lethal dose reached in preclinical toxicology

TB-500: No serious adverse events at doses up to 1260mg IV

Both peptides show favorable safety profiles in available data

Trial Exclusions

Important Considerations

Not FDA approved — investigational compoundsBanned by WADA since 2022 (S0 category)On DoD Prohibited Dietary Supplement listActive malignancy — theoretical contraindicationPregnancy or breastfeeding — not studiedQuality control issues with unregulated products

Regulatory Status

Both classified as unapproved drugs by FDA

Prescription-only in Australia and New Zealand

Not available through legitimate prescriptions in most countries

TB-500 Phase 2 trials completed for dry eye disease

Researcher Notes

No combination safety studies have been published
Individual peptide data suggests favorable safety profiles
Theoretical cancer concerns due to pro-angiogenic effects warrant caution

Frequently Asked Questions

Common questions about the Wolverine Stack

The name references the Marvel character Wolverine, known for his rapid healing abilities. BPC-157 and TB-500 are two regenerative peptides that work through different but complementary pathways — BPC-157 promotes blood vessel formation (angiogenesis) while TB-500 enhances cell migration. Together, they address multiple aspects of tissue repair, leading to the nickname 'Wolverine blend' or 'Wolverine stack' in research and athletic recovery circles.

No formal clinical trials have been published specifically on the BPC-157 + TB-500 combination. The synergistic potential is inferred from their complementary mechanisms of action and independent efficacy data. BPC-157 has over 200 preclinical studies and one Phase 1 trial, while TB-500 has completed Phase 1 and Phase 2 trials for different indications. Both peptides demonstrate convergent effects on angiogenesis and inflammation while working through distinct molecular targets.

BPC-157 primarily works through the VEGFR2-Akt-eNOS pathway to promote angiogenesis (blood vessel formation), while TB-500 primarily works through G-actin sequestration to promote cell migration and cytoskeletal remodeling. For tissue repair, you need both: blood vessels to supply nutrients and oxygen, and cells that can migrate to the injury site. Both peptides also modulate inflammatory pathways, reducing the damaging effects of chronic inflammation on healing tissues.

Both peptides individually have demonstrated favorable safety profiles. BPC-157 has no established lethal dose (LD50) in preclinical studies and shows no organ toxicity. TB-500 Phase 1 trials showed no serious adverse events at IV doses up to 1260mg daily for 14 days. However, no combination safety studies exist, and both peptides promote angiogenesis, which theoretically could affect tumor growth in individuals with undiagnosed malignancies. Neither peptide is FDA approved.

Neither BPC-157 nor TB-500 is FDA approved for human therapeutic use. They are classified as unapproved drugs by the FDA. Both are banned by WADA (World Anti-Doping Agency) under category S0 (non-approved substances), and BPC-157 is on the DoD Prohibited Dietary Supplement list. They may be available for research purposes or through compounding pharmacies in some jurisdictions, but this does not imply safety or efficacy for human use.

Both peptides have been administered via multiple routes in research settings: subcutaneous injection, intramuscular injection, intravenous infusion, and orally. BPC-157 is notably stable in gastric juice for over 24 hours, supporting oral administration. TB-500 Phase 1 trials used IV administration. There are no established combination protocols, and researchers typically derive dosing from individual peptide studies.

The lack of regulatory oversight for these compounds means purity, potency, sterility, and batch-to-batch consistency may vary significantly between suppliers. Certificates of analysis (COAs) should be evaluated, and products from reputable sources with third-party testing are recommended. Contamination with other substances or inaccurate dosing are real concerns with non-pharmaceutical grade products.

BPC-157/TB-500 (Wolverine)

Two Mechanisms, One Goal

VEGFR2 Pathway (BPC-157)

G-Actin Sequestration (TB-500)

ILK/Akt Pathway (TB-500)

Anti-Inflammatory (Both)

Complementary Regenerative Pathways

VEGFR2-Akt-eNOS Signaling Cascade

Individual Component Efficacy (Preclinical)

Component Research Highlights

Tissue Healing Effects by Component

Component Healing Acceleration

Comprehensive Tissue Repair

Cardiac Protection & Repair

Gut Protection & Healing

Neuroprotection & Recovery

BPC-157 Preclinical Protocol

TB-500 Clinical Protocol

Pharmacokinetic Profiles

⚠️Important Notes

Injection Site Reactions

Headache

GI Discomfort

Upper Respiratory

Theoretical Angiogenesis ConcernsPotential risks requiring further investigation

Combined Safety Summary

Important Considerations

💡Researcher Notes

Body Protection Compound-157

Thymosin Beta-4 (Fragment)

Why "Wolverine Stack"?

Why is this combination called the 'Wolverine Stack'?

Are there any formal studies on the combination?

How do the mechanisms complement each other?

What is the safety profile of this combination?

Are these peptides legal to use?

How are these peptides typically administered in research?

What quality concerns exist with these peptides?

BPC-157 and TB-500: Background, Indications, Efficacy, and Safety

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications

A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers

Thymosin beta4 accelerates wound healing

The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration

Modulatory effects of BPC 157 on vasomotor tone and the Src-Cav-1-eNOS signaling pathway in rats

Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds

Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

BPC-157 enhances growth hormone receptor expression in injured tendon tissue

Progress on the Function and Application of Thymosin β4

PCO-02 - Safety and Pharmacokinetics Trial (Phase 1)

BPC-157 (200+ studies) and TB-500 (170+ citations) combined research base

⚠️Important Research Notice

All the research peptides you need, with the peace of mind and research community at your fingertips.

Stay Updated with Amino Club

Important Notes

Researcher Notes